Clinical Trial Update: Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode [Phase 4]

View source ↗

Summary

Phase 4 trial updating on aripiprazole lauroxil for preventing psychotic relapse after an initial schizophrenia episode; terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• aripiprazole lauroxil (aripiprazole lauroxil)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Schizophrenia, Schizoaffective Disorder, Depressive Type | Phase 4 | Status: TERMINATED | Results posted: 2023-11-28